Cited 23 times in
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2015-04-24T17:24:00Z | - |
dc.date.available | 2015-04-24T17:24:00Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1470-2045 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105328 | - |
dc.description.abstract | Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of advanced-stage NSCLC have limited effect in countries with resource constraints. Following a systematic literature search, we present an overview of the management of advanced-stage NSCLC in the first-line setting, discuss resources required for systemic therapy, and provide treatment recommendations stratified to four resources levels. Treatment guidelines appropriate for different resource levels offer a realistic approach to management of advanced-stage NSCLC, by recognising the limitations of a particular health-care system. Although there are many barriers to cancer control in low-resource countries, these can be overcome by using measures that are culturally appropriate, economically feasible, and evidence-based. Initiatives include strategic planning, tobacco control, training of health-care workers, access to therapeutic agents, acquisition of information, public education, and alliances with established institutions and international organisations | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1102~1110 | - |
dc.relation.isPartOf | LANCET ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/economics | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/economics | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/standards | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Asia/epidemiology | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/diagnosis | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/economics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/mortality | - |
dc.subject.MESH | Congresses as Topic | - |
dc.subject.MESH | Cost-Benefit Analysis | - |
dc.subject.MESH | Developing Countries*/economics | - |
dc.subject.MESH | Drug Costs | - |
dc.subject.MESH | Evidence-Based Medicine | - |
dc.subject.MESH | Guideline Adherence | - |
dc.subject.MESH | Health Care Costs | - |
dc.subject.MESH | Health Services Accessibility | - |
dc.subject.MESH | Healthcare Disparities | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/diagnosis | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/economics | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Medical Oncology*/economics | - |
dc.subject.MESH | Medical Oncology*/standards | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Benjamin O Anderson | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Chih-Hsin Yang | - |
dc.contributor.googleauthor | Meilin Liao | - |
dc.contributor.googleauthor | Wan-Teck Lim | - |
dc.contributor.googleauthor | Peter Goldstraw | - |
dc.contributor.googleauthor | Tony S Mok | - |
dc.identifier.doi | 10.1016/S1470-2045(09)70238-4 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02154 | - |
dc.identifier.eissn | 1474-5488 | - |
dc.identifier.pmid | 19880064 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1470204509702384 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 10 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1102 | - |
dc.citation.endPage | 1110 | - |
dc.identifier.bibliographicCitation | LANCET ONCOLOGY, Vol.10(11) : 1102-1110, 2009 | - |
dc.identifier.rimsid | 54707 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.